SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules.
Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.
Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their R&D goals
Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.
Home ▸ Executive Leadership ▸ Dr. Rohtash Kumar
Rohtash is an established pharmaceutical operations leader with over two decades of experience in R&D, manufacturing, and executive leadership across global CDMO organizations. His career includes significant roles at renowned companies such as Bachem Americas, Sigma Aldrich, and Apotex. Most recently, he led Global Technology and Development at Veranova, where he drove innovation in APIs, including small molecules, peptides, oligonucleotides, and biologics. His efforts successfully advanced branded API molecules to market in collaboration with biotech partners, showcasing his ability to bridge the gap between research and commercialization.
A prolific researcher, Rohtash holds multiple patents and publications to his name. He earned his Ph.D. in Organic Chemistry from the University of Delhi, an M.Sc in Organic Chemistry, and an MBA from Chaudhary Charan Singh University. Additionally, he is a member of the American, Canadian, and Indian Medical Societies.